Our purpose was to describe a technique of atrioventricular (AV) node modification for patients with drug refractory AV nodal reentrant tachycardia (AVNRT). Nine patients (mean age, 45±20; range, 14-82) with recurrent drug refractory AVNRT (n=8) or sudden cardiac death thought to be precipitated by AVNRT (n = 1) underwent a percutaneous catheter procedure to modify AV nodal function. The area between the electrode recording the maximal His-bundle electrogram and the ostium of the coronary sinus was divided into three zones. Perinodal direct current shocks of 100-300 J were delivered to one (n=2), two (n=3), or three (n=4) zones without complications. The procedure endpoints were modification of AV conduction (either first degree AV block or complete retrograde ventriculo-atrial [VA] block) and failure to induce AVNRT before or after isoproterenol and/or atropine administration. Six of nine patients (67%) have had no inducible or spontaneous AVNRT over a mean follow-up of 12.3 ±4.1 months (range, 4.5-17). One of the six underwent repeat, successful modification, because AVNRT was inducible at restudy 2 days after the initial procedure. AVNRT recurred in three patients (33%), one early (3 days) and two late (3-4 months). Two of these patients underwent complete ablation of the AV junction and permanent pacemaker placement, whereas one is controlled with drug therapy. Therefore, AV nodal modification resulted in tachycardia control without antiarrhythmic drugs in six of nine (67%) and obviated the need for complete AV junctional ablation in seven of nine patients (78% 
open heart surgery with its attendant risk and expense.
Prior canine work in our laboratory13 showed it possible to deliver large direct current (DC) shocks in the region of the AV node without causing complete AV block. Dogs with up to one half of their AV nodes destroyed still maintained normal AV conduction. We, therefore, attempted to combine this experience with dogs and the surgical and catheter experience with humans to devise a procedure of creating lesions around the AV node using a percutaneous approach.
In this report, we explore the use of a catheter technique for the delivery of perinodal DC shocks to modify AV nodal function, such that AVNRT is abolished but AV conduction is preserved.
Methods

Clinical Data
Nine patients (mean age, 45±20 years; range, 14-82 years) with recurrent drug refractory AVNRT, or sudden cardiac death thought to be precipitated by AVNRT, underwent a percutaneous catheter procedure to modify AV nodal function. Clinical data on these eight women and one man are summarized in Table 1 .
Eight patients had recurrent symptomatic tachycardia for a mean of 10.6±7.3 years (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] years). In two (3 and 7), AVNRT was virtually incessant. These patients were refractory to or intolerant of multiple drugs (mean, 6 .5±2.1 drugs; range, 3-10 drugs). Antitachycardia pacemakers failed to improve symptoms in two patients (3 and 7). One patient (8) had sudden cardiac death with normal coronary arteries and left ventricular function. Neither ventricular tachycardia nor ventricular fibrillation could be induced during electrophysiologic testing, but AVNRT at a rapid rate was easily induced.
Baseline Electrophysiologic Study
Before attempted catheter modification, each patient underwent invasive cardiac electrophysiologic studies to determine arrhythmia mechanism. These studies were preformed in the nonsedated, postabsorptive state after cardiac medications were discontinued for at least 72 hours.
Written informed consent was obtained from all patients. Using standard 6F quadrapolar electrode catheters, electrograms were recorded from the right atrium, His bundle, right ventricle, and coronary sinus in all patients.
A standard stimulation protocol including atrial and ventricular incremental pacing and extrastimulation was performed. Intravenous isoproterenol, or atropine, or a combination was given if supraventricular tachycardia could not be induced at baseline. Isoproterenol was given as a continuous intravenous infusion, begining with 1 ,ug/min and titrated to achieve an increase in heart rate of 25-50% above baseline. Atropine was given in 0.5-mg intravenous increments to achieve the same heart rate parameters. Although there is no finding diagnostic of AVNRT, the following criteria were sought to rule out other mechanisms of SVT and support the presence of AVNRT; in all cases tachycardia induction was dependent on achievement of a critical atrio-His (AH) interval, atrial activation occurred before or simultaneous with ventricular activation, and premature ventricular stimuli introduced during inscription of the His-bundle deflection did not advance the subsequent atrial electrogram. Other findings suggestive of AVNRT were the presence of dual AV nodal pathways (discontinuous A1A2 and H1H2 curves) (five patients) and tachycardia termination with a ventricular complex that did not result in atrial activation (two patients).
Atrioventricular Nodal Modification Procedure
After obtaining informed written consent, the patients were taken to the catheterization laboratory. Two Figure 1 . The purpose of zoning was to test the hypothesis that delivery of shocks to the site of earliest retrograde atrial activation during tachycardia would result in tachycardia control. In addition, it was thought that this technique would best guide application of perinodal shocks.
Because during AVNRT, atrial and ventricular electrograms occur almost simultaneously, mapping to accurately determine the site of earliest atrial excitation was achieved by introducing single programmed ventricular extrastimuli during tachycardia at 10-msec decrements. In all patients, ventricular premature complexes could be dissociated from the tachycardia, allowing for accurate mapping of the perinodal region ( Figure 2 ).
Catheter position was determined both by use of biplane fluoroscopy (anteroposterior and right anterior oblique projections) and unipolar electrogram characteristics recorded from the mapping catheter. Three electrogram characteristics were required before delivery of the DC shocks ( Figure 3 ): 1) an atrial injury current of >0.5 mV to ensure good tissue contact, 2) nearly equal amplitudes of the atrial and ventricular electrograms (Ruder et al14 have shown that this finding reliably locates the region above the anulus and, therefore, obviates the possibility of shock delivery to the ventricle.), and 3) absence of a His-bundle deflection. In this technique, we assiduously avoided delivery of shocks to any area in which a His-bundle deflection was inscribed. This is totally different from our previously described protocol for complete AV junctional ablation, in which the largest unipolar Hisbundle deflection is used to determine the shock site.
Shocks were initially delivered to or near the site of earliest recorded perinodal atrial activation. In one patient (7), the initial shock was inadvertently delivered to zone 2, although the site of earliest retrograde atrial activation was posterior in zone 3. Patients were reevaluated after each shock. If procedure endpoints (see below) were not achieved, additional shocks were delivered to the other zones. If endpoints were achieved in any zone transiently, additional shocks of the same or higher energy were delivered to that zone. The sequence of shocks depended, in part, on our ability to reproducibly achieve the atrial electrogram characteristics desired in a given zone.
Patients were anesthetized with a short-acting intravenous barbiturate, and shocks were synchronized to the R wave on the surface ECG. DC shocks were delivered via a standard defibrillator (Life Pak 6, Redmond, Washington) between the distal electrode of the mapping catheter serving as the cathode and a large-diameter skin electrode (R2 Corp, Skokie, Illinois) on the sternum serving as the anode. In the first two patients, shocks to zone 3 were delivered between the two electrodes of the coronary sinus catheter outside the coronary sinus ostium (cathode) and the skin electrode (anode). Patients received [1] [2] [3] [4] [5] [6] [7] shocks of 100-300 J to one (n=2), two (n=3), or three (n=4) areas (Table 2) . Procedure 
Results
A summary of the baseline electrophysiologic studies is found in Table 3 . It was difficult to evaluate anterograde or retrograde conduction characteristics in some patients because atrial stimulation promptly initiated AVNRT (patients 3, 7, and 9). Dual AV nodal physiology was demonstrated in five of nine patients. AVNRT was of the common variety (anterograde conduction over a slow pathway and retrograde conduction over a faster conduction pathway) in all patients. The mean cycle length of AVNRT in these patients was 290±59 msec (range, 240-380 msec). The site of earliest retrograde atrial activation during AVNRT was localized to the anterior low right atrial septum (zone 1-2) in eight patients and the posterior low right atrial septum (zone 3) in one patient (7) . Findings Immediately Following the Procedure Immediately after the procedure, AVNRT was not inducible in any patient. Seven patients had first degree AV block, one patient (7) had complete AV block, and one patient (8) Echocardiography of all patients performed 1-3 days after the procedure showed no pericardial effusion or new valvular or wall-motion abnormalities.
Findings at Early Restudy
Repeat electrophysiologic studies of seven patients were performed after 2-4 days. Of the patients restudied, AVNRT was not inducible in six of the seven patients before and after isoproterenol and/or atropine administration. In one patient (9), although the AH required to induce AVNRT was increased from 230 to 310 msec, the induced tachycardia was associated with symptoms, and this patient underwent a repeat modification procedure. Patient Table 3 .
First-degree AV block was still present in four of seven patients (2-5), and retrograde VA block remained in two of three patients (3 and 5). AV nodal reentrant echo beats were induced in three of seven patients (2, 6, and 9). Dual AV nodal physiology was demonstrated in two (6 and 9) of the five patients who showed this before the procedure. Findings at Late Restudy At 2-4 months, restudy was performed of six patients, including the patient (9) who underwent a repeat modification procedure. The results of the six late restudies are found in Table 3 . Five patients were not inducible before or after isoproterenol and/or atropine administration. One patient (1) had inducible AVNRT and atrial tachycardia. Firstdegree AV block persisted in three patients (3, 5, and 9) , and retrograde VA block persisted in two patients (3 and 5).
Of the other three patients not restudied, two (4 and 8) had spontaneous AVNRT and one (7) had type 1 second-degree AV block with spontaneous isolated atrial echoes for 3 months but over the past 9 months has had stable first-degree AV block.
Mechanism of Tachycardia Control
The mechanism for tachycardia control varied in the six patients who underwent repeat electrophysiologic study at 2-4 months. In three (3, 5, and 9), AVNRT could not be induced because of retro- grade VA block in the fast pathway. In these patients, despite achieving AH intervals equal to or in excess of those achieved in the baseline study (which produced AVNRT), no atrial echoes could be induced. In three patients (1, 2, and 6), tachycardia control was achieved by attenuation of anterograde conduction. In these patients, although echo beats could be readily induced, sustained tachycardia could not be maintained because of anterograde block in the slow pathway. In two patients (1 and 6) with persistent dual AV nodal physiology after modification, the AV nodal refractory curves were shifted upward and to the right (Figure 4) connection. Prolongation of the HA interval in response to ventricular extrastimuli, compared with a constant short HAe during tachycardia, likewise supports the presence of an intranodal circuit. In one patient, retrograde VA conduction block was present after delivery of perinodal shocks, but after atropine, both VA conduction and isolated echo beats could be induced. These observations also suggest, but do not prove, that the retrograde limb of the tachycardia circuit involves nodal tissue.
Long-term Follow-up After a mean follow-up interval of 12.3±4.1 months, other atrial arrhythmias have been documented in four patients (Table 4 ). Three patients (1, 3, and 9) developed transient atrial tachycardia. In one (3), atrial tachycardia was initially controlled with atenolol therapy, but resolved spontaneously within 6 months, and she has been arrhythmia free without antiarrhythmic therapy for 6 months. Another patient (9) was treated with flecainide to control atrial tachycardia, but the arrhythmia resolved within 1 month and the patient has remained arrhythmia free without drugs. One patient (2) had documented episodes of paroxysmal atrial fibrillation with moderate ventricular response and is well controlled on digoxin therapy. She reports only mild palpitations occurring once every 1 to 2 months, whereas one patient (8) with recurrent AVNRT is well controlled with flecainide (no recurrences). The procedure failed in two patients (1 and 4), and both underwent complete AV junction ablation with insertion of a permanent pacemaker. One of these patients (1) showed new atrial arrhythmias. No patient has shown spontaneous progression to higher degrees of AV block during follow-up, and no patient has had syncope or presyncope after the procedure.
The five patients (3, 5-7, and 9) receiving no antiarrhythmic therapy and one patient (8) (3 and 4) . In three patients, shocks were predominantly anterior (6 and 9) or posterior (7), although more than one shock was delivered to more than one zone. In four patients, multiple shocks were delivered to all three zones.
Discussion
Eight patients with recurrent symptomatic AVNRT refractory to drug and/or device therapy (two patients) and one patient with sudden cardiac death thought to be precipitated by AVNRT underwent catheter AV nodal modification. The safety and efficacy of percutaneous catheter ablation of the AV junction and accessory pathways has been reported.7,15-22 The goal of AV nodal modification was to achieve the same degree of tachycardia control without interrupting AV conduction.
Efficacy
No spontaneous or inducible AVNRT has occurred in six of the nine patients (67%) during a follow-up of 12.3±4.1 months. These patients all had disabling symptomatic AVNRT and had failed a mean of 6.4±2.5 drugs (range, 3-10 drugs) and/or antitachycardia pacing (3 and 7). AVNRT recurred or was induced after the modification procedure in three patients (33%). One of these patients (8) has achieved tachycardia control with flecainide, whereas ablation of the AV junction with pacemaker placement was required in two patients (1 and 4) . Therefore, AV nodal modification obviated the need for AV junctional ablation with permanent pacemaker implantation in seven of nine patients (78%).
Predictors of Outcome
Due to the small number of patients, no finding clearly predicted procedure success. The number of shocks, cumulative delivered energy, and zone of shock were similar in both groups (patients with and without recurrent or inducible AVNRT). Attempting to direct initial shock location by mapping did not appear to improve success, although five patients required predominantly anterior (n = 4) or posterior (n = 1) shocks to achieve procedure end points). The data suggest that, in some patients, success may be due to nonspecific cumulative damage to the AV node rather than site specificity. The presence or absence of anterograde conduction modification or retrograde VA block immediately after the procedure was not always predictive of success. It is noteworthy that there were no recurrences in the two patients with persistent retrograde VA block. The presence or absence of AV nodal reentrant echoes at early restudy did not predict outcome.
Mechanisms of Tachycardia Control and Atrioventricular Nodal Reentrant Tachycardia
The mechanism of tachycardia control varied. Three patients had retrograde block in the fast pathway, and three patients had attenuation of anterograde conduction over the slow pathway. The precise anatomic location of these pathways is not clear. Functional,23-32 as well as anatomic32-36 data have been interpreted as being consistent with the presence of specialized His-atrial fibers, which serve as the retrograde pathway. This hypothesis serves as one rationale for recently introduced surgical procedures purportedly designed to destroy the atrial link in the tachycardia circuit. Repeated attempts to induce tachycardia after the delivery of perinodal shocks allowed for observations suggesting the His-bundle may not be a critical part of the tachycardia circuit. In one patient, for example, marked prolongation of the HV interval after DC shock was not associated with prolongation of the HAe during tachycardia. In another, inscription of otherwise classical AV nodal reentrant echo beats preceded the His-bundle deflection. An alternative explanation is that the tachycardia circuit is entirely intranodal and that various surgical or catheter ablative techniques disrupt or modify intranodal conduction. Our results are compatible with damage to both anterograde and retrograde conduction.
Adverse Effects
In four patients, supraventricular arrhythmias other than AVNRT were documented for the first time after ablation. In patient 2, paroxysms of atrial fibrillation were associated with only moderate ventricular rates and were readily controlled with digoxin therapy. Two patients developed transient atrial tachycardia that required a brief course of antiarrhythmic therapy. One patient developed complete AV block, which gradually resolved over a 4-month follow-up interval. Permanent pacing was not required for any patient. Although our results are encouraging, they must be considered as only preliminary, because the long-term effects of this procedure on AV conduction and late atrial arrhythmias are not known.
Other Reports of Atrioventricular Nodal Modification In contrast to our technique of delivering multiple perinodal shocks, Haissaguerre et a137 delivered DC shocks 5-10 mm from the site of maximal Hisbundle recording. Shocks were delivered if the His-bundle deflection was <0.1 mV and differed from our technique, which avoided delivery of shocks to areas from which any His-bundle recording was evident. In addition, they required attainment of complete retrograde VA block as the procedure end point. The efficacy and side effects reported were similar to ours except that two of their patients developed complete AV block (10%), whereas none in our report had permanent complete block. This difference may be due to either their delivery of shocks to areas recording small His-bundle deflections or the greater amounts of individual or cumulative energy delivered.
Summary
We have described a catheter technique for modification of AV nodal function by administrating DC perinodal shocks in patients with disabling or life-threatening AVNRT. We found that, in the majority of such patients, arrhythmia control was possible without resorting to total ablation of the conduction system. The only adverse eflects were initiation of new supraventricular arrhythmias (usually short lived and responsive to standard antiarrhythmic drug therapy) and the development of transient complete AV block in one patient. This procedure should be reserved for patients with AVNRT who are resistent to conventional therapy and considered suitable candidates for total AV junctional ablation.
